menu
    • menu

    Looking for excipients offered by BASF? Find information on BASF's regulatory filings (DMFs), cGMP inspections, pricing availability, etc. on PharmaCompass.

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-02-24

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-02-24

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We create chemistry for a sustainable future. In line with our corporate purpose, around 112,000 employees contribute to the success of our customers in nearly all sectors and almost every country in the world. Our broad portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. In 2015, BASF posted sales of €70 billion and income from operations before special items of app...
    We create chemistry for a sustainable future. In line with our corporate purpose, around 112,000 employees contribute to the success of our customers in nearly all sectors and almost every country in the world. Our broad portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. In 2015, BASF posted sales of €70 billion and income from operations before special items of approximately €6.7 billion. We combine economic success with environmental protection and social responsibility. Through research and innovation, we support our customers in nearly every industry.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BASFGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Carl-Bosch-Strasse 38 Ludwigshafen , Rhineland-Palatinate 67056
    Telephone
    Telephone
    +49-(0)-621-600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pharmaceutical.basf.com/global/en.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/basf-pharma-solutions/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/BASF_Pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 5423

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    First‑in‑class drugs are therapies with entirely new approaches that improve patient outcomes and fundamentally change treatment paradigms.This week, PharmaCompass brings a compilation of 2025’s most promising first-in-class drug candidates. With their US Food and Drug Administration (FDA) action dates in 2025, many of these drugs, once approved, hold the potential of becoming blockbusters.Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten poised to transform patient careIonis’ donidalorsen is an exciting candidate designed to tackle hereditary angioedema (HAE), a rare condition marked by unpredictable and potentially life‑threatening swelling episodes.This novel antisense oligonucleotide works by “silencing” the messenger RNA that codes for prekallikrein — a protein that triggers inflammation leading to swelling. Instead of blocking a protein once it’s made, donidalorsen stops the cell from producing it in the first place. This precision approach could mean fewer infusions and reduced side effects compared to traditional treatments.Another promising candidate is Sanofi and Alnylam Pharmaceuticals’ fitusiran. It employs the technology of small interfering RNA (siRNA) to lower levels of antithrombin — a natural protein that, when in excess, can impair the blood’s ability to clot. By reducing antithrombin, fitusiran rebalances the blood’s clotting process in patients with hemophilia A and B.Similarly, Cytokinetics’ aficamten is designed to treat obstructive hypertrophic cardiomyopathy (oHCM), a condition in which the heart muscle becomes abnormally thick, obstructing blood flow. Aficamten works by inhibiting cardiac myosin, a protein that drives heart muscle contraction. This helps relieve symptoms like shortness of breath and chest pain. If approved, aficamten is expected to rake in annual sales of US$ 2.8 billion by 2030.UroGen, J&J’s candidates eye US$ 5 bn markets; AbbVie, Summit’s meds target lung cancerUroGen Pharma’s UGN‑102 is poised to redefine the treatment of non‑muscle‑invasive bladder cancer. This innovative formulation uses a reverse thermal gel technology that transforms from a liquid into a gel once inside the bladder. This change ensures that the chemotherapeutic agent, mitomycin, remains in contact with the bladder lining for a longer period, increasing its effectiveness at eradicating cancer cells and reducing the risk of recurrence.For patients, UGN‑102 could mean a non‑surgical, outpatient treatment option that is less invasive than traditional surgical methods. If approved, UGN-102 could address a US market of approximately 82,000 patients annually, translating into a market opportunity exceeding US$ 5 billion, according to company estimates.Johnson & Johnson’s nipocalimab is a new treatment aimed at helping people with autoimmune diseases — a group of conditions where the body’s defense system mistakenly attacks its own healthy cells. Nipocalimab works by blocking the neonatal Fc receptor (FcRn), thereby lowering the levels of pathogenic antibodies that drive many autoimmune disorders. J&J had acquired this FcRn blocker in 2020 as part of its US$ 6.5 billion takeover of Momenta Pharmaceuticals. J&J is trialing the drug in as many as 10 indications and expects peak annual sales in excess of US$ 5 billion.AbbVie’s antibody-drug conjugate (ADC), telisotuzumab vedotin, is designed as a “guided-missile” to deliver toxic drugs directly to cancer cells while sparing healthy tissues. Telisotuzumab vedotin targets c‑Met, a receptor that is over-expressed in certain cancers such as non‑small cell lung cancer (NSCLC). There are currently no approved anti-cancer therapies specifically for c-Met over-expressing NSCLC.Summit Therapeutics’ ivonescimab is a cutting‑edge bispecific antibody designed specifically for NSCLC. Unlike traditional therapies that target a single molecule, ivonescimab binds simultaneously to a tumor-specific antigen on cancer cells and to a receptor on T cells, effectively bringing these two together so the body’s own immune system can recognize and attack the tumor. This dual engagement strategy helps overcome common mechanism tumors.Insmed’s Brensocatib is an innovative, first‐in‐class oral inhibitor of dipeptidyl peptidase‑1 (DPP‑1) that targets a key step in the inflammatory cascade. DPP‑1 is responsible for activating neutrophil serine proteases — enzymes that, when overactive, can cause significant lung tissue damage in conditions such as non‑cystic fibrosis bronchiectasis. Brensocatib is expected to clock annual sales of US$ 2.8 billion by 2030.Gepotidacin, an investigational antibiotic developed by GSK, is poised to make a significant impact in the treatment of uncomplicated urinary tract infections (uUTIs) and urogenital gonorrhea. If approved, it would be the first oral antibiotic in a new class for uUTIs in over two decades.Arrowhead, Regenxbio, Ultragenyx address rare, genetic diseasesArrowhead Pharmaceuticals is developing an innovative gene-targeting therapy — plozasiran. This drug uses RNA interference (RNAi) to interrupt the gene responsible for producing apolipoprotein C‑III (APOC3), a protein that regulates blood triglyceride levels. For people with severe hypertriglyceridemia or familial chylomicronemia syndrome (FCS) — a severe and rare genetic disease for which there are currently no FDA‑approved treatments — high triglyceride levels can lead to pancreatitis and other serious cardiovascular issues. Regenxbio’s RGX‑121 is a one‑time gene therapy candidate for Hunter syndrome (MPS 2), a rare, inherited disorder that causes progressive neurological decline. The therapy uses a harmless virus to deliver a functional copy of the gene encoding iduronate‑2‑sulfatase (I2S) directly into the central nervous system. By restoring the missing enzyme, RGX‑121 aims to slow or even reverse the harmful buildup of substances in the brain that drive the disease’s progression.Another promising candidate is Ultragenyx Pharmaceuticals’ one-time intravenous gene therapy UX111 for Sanfilippo syndrome type A (MPS 3A). This devastating disorder, which leads to severe neurodegeneration in children, currently has no effective treatment. UX111 uses an adeno‑associated virus (AAV) to deliver a working copy of the SGSH gene, the deficiency of which is responsible for the disease. By enabling the body to produce the missing enzyme, UX111 holds the promise of slowing or even halting the progression of neurodegeneration.Our viewThis year has already seen several first-in-class approvals, such as Vertex’s suzetrigine (Journavx), a pioneering non‐opioid analgesic redefining pain management; SpringWorks’ mirdametinib (Gomekli), a breakthrough MEK inhibitor for a genetic disorder that often leads to the growth of benign tumors along nerves and; AstraZeneca and Daiichi’s ADC datopotamab deruxtecan (Datroway).Despite the volatile political environment in the US and its impact on federal agencies like the FDA, we are hopeful that many of the first-in-class drugs mentioned in this article will make a debut in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 267

    https://www.pharmacompass.com/radio-compass-blog/top-first-in-class-drug-candidates-of-2025-ionis-donidalorsen-sanofi-s-fitusiran-cytokinetics-aficamten-await-fda-approval

    #Phispers by PHARMACOMPASS
    27 Feb 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    KFSHRC Detects 276 Fetal Disorders, Saving SAR 360M Annually
    KFSHRC Detects 276 Fetal Disorders, Saving SAR 360M Annually

    10 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/10/3023415/0/en/KFSHRC-Detects-276-Fetal-Genetic-Disorders-Through-Prenatal-Care-Saving-SAR-360-Million-Annually.html

    GLOBENEWSWIRE
    10 Feb 2025
    Share Share
    BASF Sells Food & Health Performance Ingredients to Louis Dreyfus
    BASF Sells Food & Health Performance Ingredients to Louis Dreyfus

    24 Dec 2024

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/basf-sells-food-and-health-performance-ingredients-business-to-louis-dreyfus-company-16572

    INDPHARMAPOST
    24 Dec 2024
    Share Share
    BASF Introduces Pepsensyal Peptide For Slow-Aging Skin Care
    BASF Introduces Pepsensyal Peptide For Slow-Aging Skin Care

    23 Oct 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/basf-introduces-pepsensyal-peptide-for-slow-aging-skin-care-solutions/

    EXPRESSPHARMA
    23 Oct 2024
    Share Share
    BASF to prepare agricultural business for IPO, Bloomberg reports
    BASF to prepare agricultural business for IPO, Bloomberg reports

    18 Sep 2024

    // REUTERS

    https://www.reuters.com/markets/europe/basf-expected-announce-listing-plans-agri-chemicals-division-reports-bloomberg-2024-09-18/

    REUTERS
    18 Sep 2024
    Share Share
    German chemical sector employers, union agree 6.85% pay hike over 20 months
    German chemical sector employers, union agree 6.85% pay hike over 20 months

    27 Jun 2024

    // REUTERS

    https://www.reuters.com/markets/commodities/german-chemical-sector-employers-union-agree-685-pay-hike-over-20-months-2024-06-27/

    REUTERS
    27 Jun 2024
    Share Share
    Signet, BASF organize Formulator’s Forum: Exchange Excipients Innovation in Hyd
    Signet, BASF organize Formulator’s Forum: Exchange Excipients Innovation in Hyd

    08 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168392&sid=2

    PHARMABIZ
    08 Apr 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Ibuprofen

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Ibuprofen

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-02-05

    Pay. Date : 2013-01-24

    DMF Number : 8709

    Submission : 1990-09-10

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2000-087 - Rev 03

    Issue Date : 2018-12-07

    Type : Chemical

    Substance Number : 721

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 217MF10984

    Registrant's Address : 100 Park Avenue, Florham Park, New Jersey, 07932, United States of America

    Initial Date of Registration : 2005-11-21

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 10117-0926

    Start Marketing Date : 2010-06-08

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Parmarine Co., Ltd.

    Registration Date : 2024-12-23

    Registration Number : 20220725-209-J-1335(1)

    Manufacturer Name : BASF Corporation

    Manufacturer Address : Highway 77 South, Bishop, Texas 78343 (5738 County Road 4, Bishop, Texas 78343), USA

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Povidone-Iodine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Povidone-Iodine

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3017

    Submission : 1977-07-22

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2008-179 - Rev 00

    Issue Date : 2015-10-21

    Type : Chemical

    Substance Number : 1142

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 217MF10985

    Registrant's Address : 100 Park Avenue, Florham Park, New Jersey, 07932, United States of America

    Initial Date of Registration : 2005-11-21

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 70177-0002

    Start Marketing Date : 2010-01-11

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Riboflavin

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Riboflavin

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 4407

    Submission : 1981-11-25

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2011-069 - Rev 00

    Issue Date : 2017-11-07

    Type : Chemical

    Substance Number : 292

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 228MF10235

    Registrant's Address : 14-16F KCCI Bldg. , 39, Sejongdaero, Jung-gu, Seoul, Republic of Korea

    Initial Date of Registration : 2016-12-26

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Icosapent Ethyl

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Icosapent Ethyl

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2020-11-02

    Pay. Date : 2020-10-20

    DMF Number : 23911

    Submission : 2010-07-07

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 223MF10118

    Registrant's Address : 4th and 5th Floors, 2 Stockport Exchange, Railway Road, Stockport, SK1 3GG, UK

    Initial Date of Registration : 2011-07-25

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Levomenthol

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Levomenthol

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2020-08-26

    Pay. Date : 2020-06-08

    DMF Number : 26711

    Submission : 2012-12-03

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2012-390 - Rev 01

    Issue Date : 2021-06-16

    Type : Chemical

    Substance Number : 619

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 48041-0001

    Start Marketing Date : 2014-07-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Omega-3-Acid Ethyl Esters 90

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Omega-3-Acid Ethyl Esters 90

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2008-132 - Rev 04

    Issue Date : 2020-01-21

    Type : Chemical

    Substance Number : 1250

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 223MF10051

    Registrant's Address : Lilleakerveien 2B, NO-0283 Oslo, Norway P. O. Box 420, NO-1327 Lysaker, Norway

    Initial Date of Registration : 2011-04-12

    Latest Date of Registration :

    EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : BASF Korea Ltd.

    Registration Date : 2012-12-27

    Registration Number : No. 6246-1-ND

    Manufacturer Name : BASF Pharma (Callanish) Ltd

    Manufacturer Address : Breasclete, Callanish, Isle of Lewis, HS2 9ED, Scotland

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Vitamin E

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Vitamin E

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 5826

    Submission : 1985-05-06

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2005-039 - Rev 02

    Issue Date : 2023-06-30

    Type : Chemical

    Substance Number : 692

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Vitamin E Acetate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Vitamin E Acetate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 5818

    Submission : 1985-05-06

    Status : Inactive

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 217MF10983

    Registrant's Address : Carl-Bosch-Strasse 38,67056 Ludwigshafen, Federal Republic of Germany

    Initial Date of Registration : 2005-11-21

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Azelaic Acid

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Azelaic Acid

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 11615

    Submission : 1995-08-04

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 48041-4700

    Start Marketing Date : 2013-01-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Octocrylene

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Generic Rx Session
    Not Confirmed
    arrow

    Octocrylene

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Generic Rx Session
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 12600

    Submission : 1997-07-17

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Acitretin

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    02

    all-rac-alpha-Tocopherol

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    03

    all-rac-alpha-Tocopheryl acetate

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    04

    Ascorbic acid

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    05

    Ascorbic acid

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    06

    Calcium ascorbate dihydrate

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    07

    Calcium Pantothenate

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    08

    Copovidone, Nominal K-value 28

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    09

    Dexpanthenol

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow

    10

    Ibuprofen

    CEP/COS

    ESF Europe
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Excipients by Ingredients

    Upload your portfolio for free, ask us

    Excipients By applications

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact BASF and get a quotation

    BASF is a supplier offers 50 products (APIs, Excipients or Intermediates).

    Find a price of Ibuprofen bulk with DMF, CEP, JDMF offered by BASF

    Find a price of Povidone-Iodine bulk with DMF, CEP, JDMF offered by BASF

    Find a price of Riboflavin bulk with CEP, JDMF offered by BASF

    Find a price of Icosapent Ethyl bulk with DMF, JDMF offered by BASF

    Find a price of Levomenthol bulk with DMF, CEP offered by BASF

    Find a price of Vitamin E bulk with CEP offered by BASF

    Find a price of 2-Phenoxyethanol bulk with CEP offered by BASF

    Find a price of Ascorbic Acid bulk offered by BASF

    Find a price of Azelaic Acid bulk with DMF offered by BASF

    Find a price of D-Panthenol bulk with CEP offered by BASF

    Find a price of Detalan bulk with DMF offered by BASF

    Find a price of Ibuprofen bulk with DMF offered by BASF

    Find a price of Ibuprofen Sodium bulk with DMF offered by BASF

    Find a price of Omega-3-Acid Ethyl Esters 90 bulk with DMF offered by BASF

    Find a price of Pantothenic Acid bulk with CEP offered by BASF

    Find a price of Polyethylene Glycol Monostearate bulk with DMF offered by BASF

    Find a price of Triclosan bulk with DMF offered by BASF

    Find a price of Vitamin A bulk with CEP offered by BASF

    Find a price of Vitamin D3 bulk with DMF offered by BASF

    Find a price of Vitamin E Acetate bulk with CEP offered by BASF

    Find a price of 5-Ethenyl-Pyrrolidin-2-One bulk offered by BASF

    Find a price of Acitretin bulk offered by BASF

    Find a price of Benzoic Acid bulk offered by BASF

    Find a price of Beta Carotene bulk offered by BASF

    Find a price of Calcium Ascorbate bulk offered by BASF

    Find a price of Diethylhexyl Phthalate bulk offered by BASF

    Find a price of Hexanedioic Acid, Polymer With 1,6-Hexanediol bulk offered by BASF

    Find a price of Isotretinoin bulk offered by BASF

    Find a price of Macrogol bulk offered by BASF

    Find a price of Paracetamol bulk offered by BASF

    Find a price of Pyridoxine Hydrochloride bulk offered by BASF

    Find a price of Riboflavin bulk offered by BASF

    Find a price of Sibutramine Hydrochloride bulk offered by BASF

    Find a price of Sodium Ascorbate bulk offered by BASF

    Find a price of Thiamine Hydrochloride bulk offered by BASF

    Find a price of Thiamine Mononitrate bulk offered by BASF

    Find a price of Tretinoin bulk offered by BASF

    Find a price of Vitamin A Acetate bulk offered by BASF

    Find a price of Vitamin A Palmitate bulk offered by BASF

    Find a price of Vitamin D3 bulk offered by BASF

    Find a price of Vitamin E bulk offered by BASF

    Find a price of STERILE AREA 1 DEPARTMENT AT MONZA FACILITY IN MILAN, ITALY. bulk offered by BASF

    Find a price of KOLLIDON 12 PF, POLYVINYLPYRROLIDONE bulk offered by BASF

    Find a price of UVINUL N539 SG bulk offered by BASF

    Find a price of RADIO-PHARMACEUTICAL SYNTHESIS MODULE << SYNTHERArV1 >> bulk offered by BASF

    Find a price of GLUCOPONA(R) 600 UP bulk offered by BASF

    Find a price of N-[1-(5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL 2-NAPHTHALENYL) bulk offered by BASF

    Find a price of LUROTIN TM CAPSULES bulk offered by BASF

    Find a price of MFG SITE FACILITIES OPERATING PROCEDURES AND PERSONEL FOR OSLO NORWAY bulk offered by BASF

    Find a price of Ibuprofen Lysinate bulk offered by BASF

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search